Literature DB >> 11467851

Protein kinase C epsilon suppresses Abeta production and promotes activation of alpha-secretase.

G Zhu1, D Wang, Y H Lin, T McMahon, E H Koo, R O Messing.   

Abstract

Deposition of plaques containing Abeta is considered important in the pathogenesis of Alzheimer's disease. Phorbol esters that activate protein kinase C (PKC) promote alpha-secretase-mediated processing of the beta amyloid precursor protein (APP), which generally reduces formation of Abeta. To determine which PKC isozymes mediate this process, we studied CHO cells that express human APP751. Phorbol 12-myristate, 13-acetate (PMA)-stimulated APP secretion, which was reduced by a general PKC inhibitor bisindoylmaleimide I, but not by Gö 6976, which inhibits PKCalpha, beta, gamma, and mu. Since PKCdelta and epsilon were the only other PMA-sensitive isozymes present, we studied cells that express selective peptide inhibitors of these isozymes. Expression of the PKCepsilon inhibitor inhibited PMA-induced APPs secretion and suppression of Abeta production. In contrast, the PKCdelta inhibitor had no effect. These results provide evidence that PKCepsilon decreases Abeta production by promoting alpha-secretase mediated cleavage of APP. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11467851     DOI: 10.1006/bbrc.2001.5273

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  Another weapon against amyloid.

Authors:  David A Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-16       Impact factor: 11.205

2.  Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon.

Authors:  Abhik Sen; Daniel L Alkon; Thomas J Nelson
Journal:  J Biol Chem       Date:  2012-03-17       Impact factor: 5.157

Review 3.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

4.  Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture.

Authors:  X Li; F Lu; Q Tian; Y Yang; Q Wang; J-Z Wang
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

5.  Phosphorylation of a UDP-glucuronosyltransferase regulates substrate specificity.

Authors:  Nikhil K Basu; Martina Kovarova; Amanda Garza; Shigeki Kubota; Tapas Saha; Partha S Mitra; Rajat Banerjee; Juan Rivera; Ida S Owens
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-21       Impact factor: 11.205

6.  Lysophosphatidic acid induces increased BACE1 expression and Aβ formation.

Authors:  Jing Shi; Yunzhou Dong; Mei-Zhen Cui; Xuemin Xu
Journal:  Biochim Biophys Acta       Date:  2012-10-02

7.  Viable mouse gene ablations that robustly alter brain Aβ levels are rare.

Authors:  Jeremy H Toyn; Xu-Alan Lin; Mark W Thompson; Valerie Guss; Jere E Meredith; Sethu Sankaranarayanan; Nestor Barrezueta; John Corradi; Antara Majumdar; Daniel L Small; Melissa Hansard; Thomas Lanthorn; Ryan S Westphal; Charles F Albright
Journal:  BMC Neurosci       Date:  2010-11-05       Impact factor: 3.288

Review 8.  BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.

Authors:  Neville Marks; Martin J Berg
Journal:  Neurochem Res       Date:  2009-09-17       Impact factor: 3.996

9.  Reduction of beta-amyloid levels by novel protein kinase C(epsilon) activators.

Authors:  Thomas J Nelson; Changhai Cui; Yuan Luo; Daniel L Alkon
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

Review 10.  The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses.

Authors:  Laura Morelli; Ramiro Llovera; Sandra Ibendahl; Eduardo M Castaño
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.